Cargando…

The long and winding road: From mouse linkage studies to a novel human therapeutic pathway in type 1 diabetes

Autoimmunity involves a loss of immune tolerance to self-proteins due to a combination of genetic susceptibility and environmental provocation, which generates autoreactive T and B cells. Genetic susceptibility affects lymphocyte autoreactivity at the level of central tolerance (e.g., defective, or...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojas, Manuel, Heuer, Luke S., Zhang, Weici, Chen, Yi-Guang, Ridgway, William M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353112/
https://www.ncbi.nlm.nih.gov/pubmed/35935980
http://dx.doi.org/10.3389/fimmu.2022.918837
_version_ 1784762803985317888
author Rojas, Manuel
Heuer, Luke S.
Zhang, Weici
Chen, Yi-Guang
Ridgway, William M.
author_facet Rojas, Manuel
Heuer, Luke S.
Zhang, Weici
Chen, Yi-Guang
Ridgway, William M.
author_sort Rojas, Manuel
collection PubMed
description Autoimmunity involves a loss of immune tolerance to self-proteins due to a combination of genetic susceptibility and environmental provocation, which generates autoreactive T and B cells. Genetic susceptibility affects lymphocyte autoreactivity at the level of central tolerance (e.g., defective, or incomplete MHC-mediated negative selection of self-reactive T cells) and peripheral tolerance (e.g., failure of mechanisms to control circulating self-reactive T cells). T regulatory cell (Treg) mediated suppression is essential for controlling peripheral autoreactive T cells. Understanding the genetic control of Treg development and function and Treg interaction with T effector and other immune cells is thus a key goal of autoimmunity research. Herein, we will review immunogenetic control of tolerance in one of the classic models of autoimmunity, the non-obese diabetic (NOD) mouse model of autoimmune Type 1 diabetes (T1D). We review the long (and still evolving) elucidation of how one susceptibility gene, Cd137, (identified originally via linkage studies) affects both the immune response and its regulation in a highly complex fashion. The CD137 (present in both membrane and soluble forms) and the CD137 ligand (CD137L) both signal into a variety of immune cells (bi-directional signaling). The overall outcome of these multitudinous effects (either tolerance or autoimmunity) depends upon the balance between the regulatory signals (predominantly mediated by soluble CD137 via the CD137L pathway) and the effector signals (mediated by both membrane-bound CD137 and CD137L). This immune balance/homeostasis can be decisively affected by genetic (susceptibility vs. resistant alleles) and environmental factors (stimulation of soluble CD137 production). The discovery of the homeostatic immune effect of soluble CD137 on the CD137-CD137L system makes it a promising candidate for immunotherapy to restore tolerance in autoimmune diseases.
format Online
Article
Text
id pubmed-9353112
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93531122022-08-06 The long and winding road: From mouse linkage studies to a novel human therapeutic pathway in type 1 diabetes Rojas, Manuel Heuer, Luke S. Zhang, Weici Chen, Yi-Guang Ridgway, William M. Front Immunol Immunology Autoimmunity involves a loss of immune tolerance to self-proteins due to a combination of genetic susceptibility and environmental provocation, which generates autoreactive T and B cells. Genetic susceptibility affects lymphocyte autoreactivity at the level of central tolerance (e.g., defective, or incomplete MHC-mediated negative selection of self-reactive T cells) and peripheral tolerance (e.g., failure of mechanisms to control circulating self-reactive T cells). T regulatory cell (Treg) mediated suppression is essential for controlling peripheral autoreactive T cells. Understanding the genetic control of Treg development and function and Treg interaction with T effector and other immune cells is thus a key goal of autoimmunity research. Herein, we will review immunogenetic control of tolerance in one of the classic models of autoimmunity, the non-obese diabetic (NOD) mouse model of autoimmune Type 1 diabetes (T1D). We review the long (and still evolving) elucidation of how one susceptibility gene, Cd137, (identified originally via linkage studies) affects both the immune response and its regulation in a highly complex fashion. The CD137 (present in both membrane and soluble forms) and the CD137 ligand (CD137L) both signal into a variety of immune cells (bi-directional signaling). The overall outcome of these multitudinous effects (either tolerance or autoimmunity) depends upon the balance between the regulatory signals (predominantly mediated by soluble CD137 via the CD137L pathway) and the effector signals (mediated by both membrane-bound CD137 and CD137L). This immune balance/homeostasis can be decisively affected by genetic (susceptibility vs. resistant alleles) and environmental factors (stimulation of soluble CD137 production). The discovery of the homeostatic immune effect of soluble CD137 on the CD137-CD137L system makes it a promising candidate for immunotherapy to restore tolerance in autoimmune diseases. Frontiers Media S.A. 2022-07-22 /pmc/articles/PMC9353112/ /pubmed/35935980 http://dx.doi.org/10.3389/fimmu.2022.918837 Text en Copyright © 2022 Rojas, Heuer, Zhang, Chen and Ridgway https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Rojas, Manuel
Heuer, Luke S.
Zhang, Weici
Chen, Yi-Guang
Ridgway, William M.
The long and winding road: From mouse linkage studies to a novel human therapeutic pathway in type 1 diabetes
title The long and winding road: From mouse linkage studies to a novel human therapeutic pathway in type 1 diabetes
title_full The long and winding road: From mouse linkage studies to a novel human therapeutic pathway in type 1 diabetes
title_fullStr The long and winding road: From mouse linkage studies to a novel human therapeutic pathway in type 1 diabetes
title_full_unstemmed The long and winding road: From mouse linkage studies to a novel human therapeutic pathway in type 1 diabetes
title_short The long and winding road: From mouse linkage studies to a novel human therapeutic pathway in type 1 diabetes
title_sort long and winding road: from mouse linkage studies to a novel human therapeutic pathway in type 1 diabetes
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353112/
https://www.ncbi.nlm.nih.gov/pubmed/35935980
http://dx.doi.org/10.3389/fimmu.2022.918837
work_keys_str_mv AT rojasmanuel thelongandwindingroadfrommouselinkagestudiestoanovelhumantherapeuticpathwayintype1diabetes
AT heuerlukes thelongandwindingroadfrommouselinkagestudiestoanovelhumantherapeuticpathwayintype1diabetes
AT zhangweici thelongandwindingroadfrommouselinkagestudiestoanovelhumantherapeuticpathwayintype1diabetes
AT chenyiguang thelongandwindingroadfrommouselinkagestudiestoanovelhumantherapeuticpathwayintype1diabetes
AT ridgwaywilliamm thelongandwindingroadfrommouselinkagestudiestoanovelhumantherapeuticpathwayintype1diabetes
AT rojasmanuel longandwindingroadfrommouselinkagestudiestoanovelhumantherapeuticpathwayintype1diabetes
AT heuerlukes longandwindingroadfrommouselinkagestudiestoanovelhumantherapeuticpathwayintype1diabetes
AT zhangweici longandwindingroadfrommouselinkagestudiestoanovelhumantherapeuticpathwayintype1diabetes
AT chenyiguang longandwindingroadfrommouselinkagestudiestoanovelhumantherapeuticpathwayintype1diabetes
AT ridgwaywilliamm longandwindingroadfrommouselinkagestudiestoanovelhumantherapeuticpathwayintype1diabetes